SANJAY MATHEW to Anti-Anxiety Agents
This is a "connection" page, showing publications SANJAY MATHEW has written about Anti-Anxiety Agents.
Connection Strength
2.340
-
Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012.
Score: 0.639
-
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66.
Score: 0.295
-
Anxiety and depression: leading edge of therapy. Mt Sinai J Med. 2008 May-Jun; 75(3):171-3.
Score: 0.288
-
Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008 May-Jun; 75(3):248-62.
Score: 0.288
-
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8.
Score: 0.278
-
Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83.
Score: 0.274
-
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
Score: 0.108
-
Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7.
Score: 0.098
-
Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002 Nov 15; 52(10):1008-30.
Score: 0.049
-
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93.
Score: 0.021